This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations. The study is conducted in routine practice setting hence no interference with standard care takes place. Pharmacologic treatments of MS-fatigue and depression will also be recorded.
Study Type
OBSERVATIONAL
Enrollment
567
Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
Unnamed facility
Many Locations, Poland
Changes of fatigue score over time
Time frame: short-term, mid-term and long-term changes will be assessed: 3 months vs. baseline, 6 months vs. baseline and 12 months vs. baseline
Changes of depression score over time
Time frame: short-term, mid-term and long-term changes will be assessed: 3 months vs. baseline, 6 months vs. baseline and 12 months vs. baseline
Treatment adherence
Time frame: 12 months
Clinical course of the disease
Time frame: 12 months
Overall treatment tolerability as measured by rate of adverse events
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.